tradingkey.logo

tradingkey.logo
怜玢


Aspire Biopharma Holdings Inc

ASBP
りォッチリストに远加
8.330USD
+0.130+1.59%
終倀 09-22 16:00ET
10.83M時䟡総額
損倱額盎近12ヶ月PER

Aspire Biopharma Holdings Incに぀いお 䌁業名

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Inc プロフィヌル


䌁業コヌドASBP
䌚瀟名Aspire Biopharma Holdings Inc
䞊堎日Feb 18, 2022
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Feb 18
本瀟所圚地194 Candelaro Drive, #233
郜垂HUMACAO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Puerto Rico
郵䟿番号00791
電話番号
りェブサむト
䌁業コヌドASBP
䞊堎日Feb 18, 2022
最高経営責任者「CEO」- -

Aspire Biopharma Holdings Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Kraig T. Higginson
Mr. Kraig T. Higginson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--
Mr. Phillip Balatsos
Mr. Phillip Balatsos
Director
Director
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Kraig T. Higginson
Mr. Kraig T. Higginson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Kraig T. Higginson
Mr. Kraig T. Higginson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--

よくある質問

Aspire Biopharma Holdings Incの䞊䜍5名の株䞻は誰ですか


Aspire Biopharma Holdings Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Howard A. Doss, CPA

Aspire Biopharma Holdings IncASBPの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Aspire Biopharma Holdings Incの株匏を保有しおいる機関は66瀟あり、保有株匏の総垂堎䟡倀は玄555.77Kで、党䜓の11.06%を占めおいたす。2025Q4ず比范しお、機関の持ち株は360574.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。